Ocuphire Announces Financial Results for the First Quarter 2021 and Provides Corporate UpdateGlobeNewsWire • 05/07/21
Ocuphire's APX3330 for Retinal Diseases to be Presented at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual MeetingGlobeNewsWire • 04/22/21
Ocuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 in Diabetic RetinopathyGlobeNewsWire • 04/08/21
Ocuphire Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary EndpointGlobeNewsWire • 03/15/21
Ocuphire Announces Financial Results for the Full Year 2020 and Provides Corporate UpdateGlobeNewsWire • 03/10/21
Ocuphire Announces Publication of MIRA-1 Phase 2b Results in Optometry and Visual Science Demonstrating Reduction of Pharmacologically Induced Mydriasis by Nyxol®GlobeNewsWire • 03/05/21
Ocuphire Initiates Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in PresbyopiaGlobeNewsWire • 02/18/21
Ocuphire to Participate in the 2021 BIO CEO & Investor Conference and Cantor Fitzgerald's Panel on Eyeing Key Events in the Ophthalmology Space in 2021GlobeNewsWire • 02/11/21
Ocuphire Announces Publication of ORION-1 Phase 2 Results for Nyxol in Clinical Ophthalmology and Presentation at the January OIS Presbyopia Innovation ShowcaseGlobeNewsWire • 01/20/21
Ocuphire to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event in Early January 2021GlobeNewsWire • 12/30/20